Pharmaceutical Mergers Transactions worth 260 Billion Dollars in Pharmaceutical and Biotech

Editor: Dominik Stephan

A record transaction volume in pharmaceutical, medical and biotech markets: Global M&A activities during the first half of 2014 hit the highest half-year value on since 2001, with US $ 260.2 billion-worth of deals, Mergermarket states. This is a whopping 227.8% increase from the same period in 2013.

Related Vendors

(Picture: PROCESS)

The value so far in 2014 is already higher than the annual value for the last eight years. Q2 which saw the announcement of 277 deals valued at US $ 195 billion, increased values by 199.5% from Q2 2013 (US$ 65.1 billionn) and by 199% from the previous quarter (US$ 65.2 billion)

The massive increase is mainly due to the announcement of six mega-deals so far this year amounting to a combined total of US$ 156.9 billion, versus two announced in H1 2013 totalling just US$ 27.4 billion. The mega-deals all accounted for 60.3% of the total activity in the sector. The top two deals, each valued over US$ 45 billion, represent the fifth and sixth highest valued PMB deal record

PMB, which was only the fifth most active sector in Q1 2014 as well as in H1 last year, was the most active sector globally and accounted for 16.4% of the global M&A value (US$ 1,582.9 billion). A stark contrast to a 7.9% a market share in H1 2013.